Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This is a phase II multicenter study including breast cancer patients with chest wall disease
that is hormone resistant (estrogen receptor (ER) positive/progesterone receptor (PR)
positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer with
progressive disease on 2 prior lines of hormonal therapy) or triple negative (ER negative/PR
negative/HER2 negative, TNBC). Eighty-four patients will be enrolled at Translational Breast
Cancer Research Consortium (TBCRC) sites and will be randomized 2:1 to receive treatment with
pembrolizumab and carboplatin (n=56, Arm A) or carboplatin alone (n=28, Arm B) until
documented disease progression. Patients randomized to Arm B may cross-over following
progression to pembrolizumab with or without carboplatin at investigator's discretion (Arm
Bx). Patients may have received any number of prior lines of chemotherapy. Patients in Arm A
will be treated with pembrolizumab 200 mg IV and carboplatin area under curve (AUC) 5 IV
every 3 weeks for at least 6 cycles followed by maintenance pembrolizumab 200 mg IV every 3
weeks if stable or responding disease. Patients in Arm B will be treated with carboplatin AUC
5 IV every 3 weeks until progression, whereupon they may cross-over to pembrolizumab 200 mg
IV every 3 weeks with or without carboplatin at investigator's discretion (Arm Bx). An
interim analysis for futility will be performed after 18 patients are enrolled into Arm B to
allow early stopping of that trial arm for lack of efficacy. The primary endpoint is to
compare disease control rates at 18 weeks of treatment. Secondary endpoints include
progression free survival, toxicity, and overall response rate.
Phase:
Phase 2
Details
Lead Sponsor:
Hope Rugo, MD University of California, San Francisco
Collaborators:
Johns Hopkins University Massachusetts General Hospital Mayo Clinic Merck Sharp & Dohme Corp. Translational Breast Cancer Research Consortium